Bios Equity COF, LP - Director, 10%+ Owner at Actuate Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Company
Role
Director, 10%+ Owner
Stock Symbol
ACTU on Nasdaq
All Insider Reports
All Insider Reports

There are no Buy or Sell transactions made by Bios Equity COF, LP since 11/5/2023

Holdings reported by Bios Equity COF, LP for Actuate Therapeutics, Inc.

Class Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 980K Aug 14, 2024 Directly held by Bios Fund II QP, LP
Common Stock 300K Aug 14, 2024 Directly held by Bios Fund II, LP
Common Stock 131K Aug 14, 2024 Directly held by Bios Fund II NT, LP
Stock Options 31.9K Aug 12, 2024 Directly held by BP Directors, LP Common Stock 31.9K
Stock Options 15K Aug 12, 2024 Directly held by Aaron G.L. Fletcher Common Stock
Convertible Note 0 Aug 14, 2024 Directly held by Bios Clinical Opportunity Fund, LP Common Stock
Series A Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund I, LP Common Stock
Series A Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund I QP, LP Common Stock
Series B-1 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Actuate Co-Invest I, LP Common Stock
Series B-1 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II, LP Common Stock
Series B-1 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II NT, LP Common Stock
Series B-1 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II QP, LP Common Stock
Series B-2 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Actuate Co-Invest I, LP Common Stock
Series B-2 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II, LP Common Stock
Series B-2 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II NT, LP Common Stock
Series B-2 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II QP, LP Common Stock
Series B-3 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II, LP Common Stock
Series B-3 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II NT, LP Common Stock
Series B-3 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund II QP, LP Common Stock
Series B-4 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Actuate Co-Invest II, LP Common Stock
Series B-4 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund III, LP Common Stock
Series B-4 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund III NT, LP Common Stock
Series B-4 Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund III QP, LP Common Stock
Series C Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Actuate Co-Invest III, LP Common Stock
Series C Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund III, LP Common Stock
Series C Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund III NT, LP Common Stock
Series C Redeemable Convertible Preferred Stock 0 Aug 14, 2024 Directly held by Bios Fund III QP, LP Common Stock
Warrant (Right to Buy) 0 Aug 14, 2024 Directly held by Bios Fund II, LP Common Stock
Warrant (Right to Buy) 0 Aug 14, 2024 Directly held by Bios Fund II NT, LP Common Stock
Warrant (Right to Buy) 0 Aug 14, 2024 Directly held by Bios Fund II QP, LP Common Stock

Transactions reported by Bios Equity COF, LP for Actuate Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.